If you or your child has been diagnosed with IgA vasculitis, you have probably already met it by its older, more famous name: Henoch-Schönlein purpura, or HSP. You have likely watched the strange, alarming rash bloom across the buttocks and shins, felt the ache settle into the ankles and knees, and braced through bouts of crampy abdominal pain. And if a doctor has asked you to keep collecting urine samples for the better part of a year, you have learned that the part of this disease that matters most happens where you cannot see it, in the kidneys.

This page is not here to sell you a cure. IgA vasculitis is a real immune-mediated disease with a defined pathophysiology, and the most important part of care is monitoring and physician oversight, especially for the kidneys and, in children, for the gut. What this page does offer is a careful, honest walk through how wildcrafted sea moss intersects with the genuine biology of this condition. Sea moss delivers fucoidan, a sulfated marine polysaccharide studied for its effects on inflammatory signaling and mucosal immunity, alongside selenium, omega-3 precursors, zinc, iodine, and a broad spectrum of trace minerals. Several of those touch pathways that sit right at the center of how IgA vasculitis works. We will name where the science is interesting, where it is only preclinical, and where a related condition (IgA nephropathy) has actual human trial data that is worth understanding.

What Is IgA Vasculitis?

IgA vasculitis, formerly called Henoch-Schönlein purpura (HSP), is a small-vessel vasculitis: an inflammation of the smallest blood vessels (capillaries, venules, and small arterioles) driven by the deposition of immune complexes containing immunoglobulin A (IgA). It is the most common form of vasculitis in children, with most cases appearing between ages three and ten, often a week or two after an upper respiratory infection. Adults can develop it too, and when they do, the disease tends to behave more aggressively, with a higher likelihood of serious kidney involvement.

The hallmark of IgA vasculitis is a specific kind of immune deposit: IgA1-dominant immune complexes lodged in the walls of small vessels and, critically, in the mesangium of the kidney. That same molecular fingerprint connects it to a related kidney disease, IgA nephropathy (Berger's disease), and understanding that connection is central to understanding why kidney monitoring matters so much.

The Clinical Tetrad

IgA vasculitis classically presents as a tetrad of four features, though not every patient shows all four, and they may appear in any order:

• Palpable purpura. The defining sign. Raised, non-blanching purple-red spots that you can feel as well as see, distributed symmetrically over the buttocks and the extensor surfaces of the lower legs. Crucially, this purpura is non-thrombocytopenic, meaning the platelet count is normal; the bleeding into the skin comes from inflamed vessel walls, not from a clotting deficiency. This distinguishes it from other causes of purpura at a glance to the trained eye.
• Arthritis and arthralgia. Joint pain and swelling, most often in the ankles and knees, affecting a majority of patients. It is typically transient and non-deforming, resolving without permanent damage, but it can be painful enough to keep a child from walking.
• Abdominal pain. Colicky, crampy abdominal pain from vasculitis of the gut vessels, sometimes with nausea, vomiting, or gastrointestinal bleeding. In children this carries a specific danger: the inflamed bowel wall can act as a lead point for intussusception, where one segment of intestine telescopes into another, a surgical emergency.
• Renal involvement. The feature that drives long-term prognosis. Between 30 and 50 percent of patients develop some degree of kidney involvement, ranging from microscopic blood in the urine (hematuria) to significant protein loss (proteinuria), and in some cases a glomerulonephritis that mirrors IgA nephropathy. This is why monitoring continues long after the rash has faded.

Classification Criteria: ACR 1990 vs EULAR/PRINTO/PRES 2010

Two main sets of classification criteria are used. The older American College of Rheumatology (ACR) 1990 criteria for HSP required two of four features: palpable purpura, age 20 or younger at onset, bowel angina (abdominal pain), and biopsy showing granulocytes in the walls of small vessels. The more recent EULAR/PRINTO/PRES 2010 criteria, developed specifically with pediatric vasculitis in mind, require purpura or petechiae with lower-limb predominance as a mandatory criterion, plus at least one of: diffuse abdominal pain, arthritis or arthralgia, renal involvement (hematuria or proteinuria), or a biopsy showing IgA deposition. The 2010 criteria's insistence on the characteristic purpura and on IgA-specific histology reflects a sharper modern understanding of the disease as an IgA-driven process.

The Pathophysiology: How IgA Vasculitis Actually Works

The deeper story of IgA vasculitis is a story about a single, subtly defective antibody molecule and the chain reaction it sets off. Understanding it is what makes the discussion of nutrients meaningful rather than hand-waving, because the relevant sea moss components have been studied against specific links in this chain.

Galactose-Deficient IgA1 (Gd-IgA1): The Molecular Flaw

At the root of IgA vasculitis (and its kidney cousin, IgA nephropathy) lies an abnormality in a specific antibody: IgA1. Normal IgA1 carries sugar chains (O-linked glycans) in its hinge region, and those chains are normally capped with galactose. In susceptible people, a fraction of IgA1 is produced with under-galactosylated hinge sugars, a molecule called galactose-deficient IgA1, or Gd-IgA1. Because the galactose cap is missing, the underlying sugar, N-acetylgalactosamine (GalNAc), is left exposed where it should not be. This aberrant O-glycosylation is the original molecular flaw from which everything else cascades.

Anti-Glycan Antibodies and Immune Complex Formation

That exposed GalNAc looks foreign to the immune system. The body responds by producing anti-glycan antibodies, typically IgG (and sometimes IgA) directed against the exposed sugar, known as anti-Gd-IgA1 antibodies. When these anti-glycan IgG antibodies bind the galactose-deficient IgA1, they form circulating IgA1-IgG immune complexes. These complexes are the pathogenic engine of the disease. Too large to be cleared efficiently, they deposit in the walls of small vessels throughout the skin, joints, and gut, and they deposit in the mesangium of the kidney, the central supporting tissue of the glomerular filter.

Complement Activation

Immune complex deposition alone is not enough to cause the tissue damage; it recruits the complement system, an ancient cascade of blood proteins that amplifies inflammation. In IgA vasculitis, complement is activated predominantly through two routes, with the classical pathway notably spared (consistent with IgA's inability to fix complement classically):

• The lectin pathway. IgA-containing immune complexes can activate complement via the lectin pathway, through mannose-binding lectin and the associated MASP proteases. Lectin pathway activation is a recognized contributor to the glomerular injury in IgA-mediated kidney disease, and its presence on biopsy is associated with more severe disease.
• The alternative pathway and C3. The alternative pathway amplifies complement activation, depositing C3 in the vessel walls and mesangium. C3 deposition alongside IgA on biopsy is a characteristic finding.
• The membrane attack complex (MAC). Terminal complement activation assembles the C5b-9 membrane attack complex, which can directly injure cells and further inflame the vessel and glomerular tissue.

Cytokines, Neutrophils, and the Inflammatory Storm

Once complexes deposit and complement fires, the local environment fills with inflammatory mediators that recruit immune cells and damage the vessel wall:

• Neutrophil recruitment. Neutrophils flood into the vessel walls (a leukocytoclastic vasculitis), and their breakdown products and enzymes inflict much of the visible damage that produces palpable purpura.
• IL-6, TNF-α, and IL-17. Pro-inflammatory cytokines including interleukin-6, tumor necrosis factor-alpha, and IL-17 (the signature cytokine of Th17 cells) are elevated and drive the inflammatory amplification. NF-κB, the master transcriptional switch for inflammation, sits upstream of much of this cytokine production.
• APRIL and BAFF. Two cytokines of the TNF family, APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor), are elevated in IgA-mediated disease. They promote the class switching of B cells toward IgA production and the survival of IgA-producing plasma cells, effectively feeding the very Gd-IgA1 that starts the whole process. Drugs targeting APRIL and BAFF are now in clinical trials for IgA nephropathy, which tells you how central this axis is believed to be.

The Trigger: Upper Respiratory Infection

In a majority of pediatric cases, IgA vasculitis follows an upper respiratory infection by one to two weeks. Streptococcal infection is a classic precipitant, and various viruses are also implicated. The leading explanation ties back to mucosal immunity: an infection at a mucosal surface (the throat, the gut) stimulates IgA production, and in susceptible individuals that surge includes a wave of galactose-deficient IgA1, setting off the immune complex cascade. This mucosal angle is precisely where the gut-barrier discussion around fucoidan becomes relevant.

Sea Moss Nutrients and the Biology of IgA Vasculitis

Sea moss is not a single drug; it is a whole food carrying a marine polysaccharide and a wide mineral spectrum. Below, each major component is mapped onto the specific pathways above, with the honest limits stated plainly. None of this is a claim that sea moss treats or alters the disease; it is a description of where its nutrients may support the body's own systems that touch this biology.

Fucoidan: The Marine Polysaccharide With Many Touchpoints

Fucoidan is the most mechanistically interesting compound in sea moss for an immune-complex vasculitis. It is a sulfated polysaccharide, and that dense sulfation underlies a range of effects studied in laboratory and animal models that happen to line up with several nodes of IgA vasculitis biology:

• NF-κB suppression and cytokine reduction. Fucoidan has repeatedly been shown to dampen NF-κB signaling, the master inflammatory switch, with downstream reductions in IL-6, TNF-α, and IL-17-associated inflammation in preclinical systems. Those are precisely the cytokines elevated in the vasculitic inflammation of IgA vasculitis.
• Complement lectin pathway modulation. Sulfated polysaccharides, fucoidan among them, have been studied for their ability to modulate complement activation, including effects relevant to the lectin pathway that participates in IgA-mediated injury. Tempering excessive complement amplification is mechanistically appealing in a complement-driven vasculitis.
• Potential APRIL/BAFF and IgA class-switch modulation. Because gut-associated mucosal immunity drives APRIL/BAFF signaling and IgA class switching, and because fucoidan acts on gut immune signaling, there is preclinical interest in whether marine polysaccharides could influence the mucosal B-cell signals that feed IgA production. This is early and speculative, not established, but it sits squarely on the disease's central axis.
• Gut mucosal barrier support. Fucoidan has prebiotic and barrier-supporting properties in models, reinforcing the intestinal lining and shaping the microbiome. Since mucosal infections and a leaky gut barrier are implicated in triggering the IgA surges that start the disease, supporting a healthy gut barrier is biologically coherent as foundational support, helping reduce the microbial triggers reaching the mucosal immune system.
• Anti-neutrophil activity. Fucoidan can modulate neutrophil recruitment and activation in experimental inflammation, relevant to the neutrophil-driven (leukocytoclastic) damage in the vessel walls.
• Mesangial context. In kidney injury models, fucoidan and related sulfated polysaccharides have shown anti-inflammatory and protective signals in the mesangial and glomerular environment, the very tissue where IgA immune complexes deposit.

Selenium: Antioxidant Defense for the Kidney and Beyond

Oxidative stress is a feature of glomerular inflammation, and the kidney is the organ whose involvement decides the long-term prognosis in IgA vasculitis. Selenium sits at the active site of a key family of antioxidant enzymes and supports immune regulation:

• GPx1 and GPx2 in renal and mucosal tissue. The selenium-dependent glutathione peroxidases neutralize hydrogen peroxide and lipid peroxides. GPx1 is widely expressed (including in renal tubular cells and the mesangium), and GPx2 protects the gut epithelium, the mucosal surface so central to IgA biology. Adequate selenium keeps these enzymes working.
• Thioredoxin reductase (TrxR1). This selenoenzyme maintains the thioredoxin antioxidant system, limiting the oxidative stress that accompanies glomerulonephritis and tissue inflammation.
• Selenoprotein P. The body's main selenium-transport protein also carries antioxidant activity and is relevant to renal selenium status and protection of vascular and tubular tissue.
• Immune regulation and renal function markers. Selenium status is linked to balanced immune responses and to several markers of renal function in population studies. The goal is healthy baseline status, supporting the body's own antioxidant defense in tissues under inflammatory stress.

Sea moss supplies selenium in the organic selenomethionine form found in foods, which the body recognizes and incorporates efficiently. The aim is sufficiency, not megadosing; selenium has a narrow safe window, and excess is harmful.

Omega-3 (EPA/DHA): The One Place With Real Human Trial Data

This is the most important nutrient section on the page, because it is the only one with serious human clinical evidence, and that evidence is in IgA nephropathy, the kidney disease that shares its core mechanism with the renal arm of IgA vasculitis.

• The Donadio fish oil trials. In a landmark randomized controlled trial published in the New England Journal of Medicine in 1994, Donadio and colleagues at the Mayo Clinic gave patients with IgA nephropathy roughly 12 grams per day of fish oil (a high dose of EPA and DHA) and found that it slowed the decline of kidney function compared with placebo over the study period. A follow-up report in 1999 reinforced the longer-term benefit on preserving renal function. These trials are why omega-3s entered the conversation for IgA-mediated kidney disease and remain part of some treatment discussions today.
• Resolvins and protectins. EPA and DHA are the precursors of specialized pro-resolving mediators, resolvins and protectins, that actively switch off inflammation rather than merely blunting it, relevant to resolving the inflammatory injury in glomerular and vascular tissue.
• PGE2 and LTB4 suppression in the mesangium. Omega-3s shift eicosanoid production away from the pro-inflammatory prostaglandin E2 and leukotriene B4, mediators active in the inflamed mesangium, toward less inflammatory species.
• Proteinuria. By reducing glomerular inflammation, omega-3 supplementation has been associated in some studies with effects on proteinuria, the protein-in-urine marker that drives prognosis in IgA-mediated kidney disease.

Zinc: Mucosal IgA Regulation and Immune Balance

Zinc is a quietly important mineral for exactly the mucosal and immune systems that IgA vasculitis hinges on:

• Mucosal IgA regulation. Zinc is involved in the regulation of mucosal immunity and IgA production at gut and respiratory surfaces, the very compartments where the disease-driving IgA surges originate.
• FOXP3+ regulatory T cells. Zinc supports the induction and function of FOXP3-expressing regulatory T cells (Tregs), the immune cells that restrain overactive responses. In an immune-complex disease, supporting that regulatory brake is mechanistically appealing.
• Gut-associated lymphoid tissue (GALT). GALT, the immune tissue of the gut, is zinc-dependent for normal function. The intestinal zinc transporter ZIP4 governs zinc uptake in the gut, and its activity influences mucosal immune health, where IgA class switching is shaped.
• Wound healing and purpura. Zinc is essential for tissue repair and the healing of the damaged skin and vessel walls that produce purpura.
• Complement. Zinc participates in the structure and regulation of several complement-related proteins, tying it loosely to the complement arm of the disease.

Sea moss provides zinc within its broad mineral profile, contributing to the foundational nutritional status that mucosal immunity and immune regulation depend on.

Iodine: Thyroid Support and Tolerability

Iodine is less directly relevant to the core mechanism of IgA vasculitis than the nutrients above, but it deserves mention, particularly for adult patients. Iodine is required for the thyroid to make its hormones, and balanced thyroid status supports general metabolic and immune health. For adults with IgA vasculitis, normal thyroid function is one element of overall wellbeing during an inflammatory illness.

The Disease Mechanism, Step by Step

Reading the cascade this way clarifies the honest framing of sea moss. Conventional care monitors the kidney end of this chain and, in severe cases, suppresses the inflammation with medication. Fucoidan, selenium, omega-3, and zinc have been studied for effects scattered across the earlier steps, complement, NF-κB-driven cytokines, neutrophil activity, mucosal IgA regulation, and oxidative injury, but as foods and largely preclinical findings, with the single exception of the omega-3 trials in IgA nephropathy. They may support some people as nutritional companions; they are not substitutes for monitoring or for the medications used in severe disease.

IgA Vasculitis vs IgA Nephropathy (Berger's Disease)

Because these two conditions share a mechanism, it helps to lay out exactly how they relate and differ.

• Shared engine. Both are driven by galactose-deficient IgA1 and anti-glycan immune complexes that deposit in the kidney mesangium and activate complement. The kidney biopsy can look identical.
• The key difference is reach. IgA nephropathy is largely confined to the kidney, often discovered incidentally as blood or protein in the urine. IgA vasculitis is the systemic form, adding the skin (purpura), joints (arthritis), and gut (abdominal pain) to the same underlying process.
• Demographics. IgA vasculitis is predominantly a childhood disease that often follows an infection and frequently resolves; IgA nephropathy more often presents in older children and adults and is a leading cause of chronic kidney disease worldwide.
• Why it matters for this page. The strongest nutrient evidence relevant here, the Donadio omega-3 trials, comes from IgA nephropathy, and it informs the renal arm of IgA vasculitis precisely because the kidney injury is mechanistically the same.

Diagnosis and Monitoring

Diagnosis is often clinical, made on the recognizable picture of palpable purpura with joint, gut, or kidney features, but tissue and laboratory findings confirm and refine it.

• Skin biopsy with direct immunofluorescence (DIF). A biopsy of the purpuric skin shows leukocytoclastic vasculitis, and DIF reveals IgA deposits in the walls of the small vessels, the histologic signature that anchors the diagnosis.
• Renal biopsy. When kidney involvement is significant (heavy proteinuria, declining function, or nephritic features), a kidney biopsy may be done. It shows mesangial IgA deposition and is graded for the degree of crescent formation and scarring, which guides treatment of the nephritis.
• Urinalysis monitoring. This is the cornerstone of follow-up. Because kidney involvement can appear weeks to months after the rash, guidelines recommend repeated urinalysis (checking for blood and protein) and blood pressure monitoring over an extended window, commonly for six to twelve months and sometimes longer, even when the child looks well.

Treatment Overview

For most children, IgA vasculitis is self-limited and the mainstay is supportive care: rest, hydration, and pain control, with vigilant monitoring of the kidneys and gut. More involved disease calls for specific therapies, all of which are prescribed and supervised by a physician.

• Supportive care. Most pediatric cases resolve over weeks with supportive management alone. Pain from arthritis and abdominal cramping is managed symptomatically under medical guidance.
• Corticosteroids. Used for severe gastrointestinal involvement (significant pain, bleeding) and for significant renal involvement, to dampen the inflammatory injury.
• Azathioprine and mycophenolate mofetil (MMF). Immunosuppressants added for persistent or severe nephritis that does not settle with steroids alone.
• ACE inhibitors (and ARBs). Used to reduce proteinuria and protect the kidney over the long term, a strategy borrowed from the broader management of glomerular disease.
• Dapsone. Sometimes used for persistent or recurrent skin disease (purpura) that does not resolve.
• IVIG and rituximab. Reserved for refractory or unusually severe cases that fail standard therapy.

Renal Prognosis: Adults vs Children

The kidney is the organ that determines long-term outcome, and here the difference between children and adults is stark.

• Children. The great majority recover fully. Kidney involvement, when it occurs, is often mild and transient, and progression to chronic kidney disease is uncommon. Still, because a minority do develop persistent nephritis, monitoring is non-negotiable.
• Adults. Adult-onset IgA vasculitis is more severe and more likely to involve the kidneys, and a meaningful fraction, on the order of 20 to 30 percent in various series, can progress to chronic kidney disease over time. Adults are also more likely to need immunosuppressive treatment.
• Monitoring protocol. Because nephritis can emerge after the visible disease fades, guidelines advise repeated urinalysis and blood pressure checks over a one-to-two-year window following diagnosis. This is the single most important ongoing task in IgA vasculitis care, and no supplement changes the need for it.

Gastrointestinal Manifestations

The gut is the second organ system that can turn IgA vasculitis from an inconvenience into an emergency, especially in children.

• Intussusception. The inflamed, edematous bowel wall can act as a lead point, allowing one segment of intestine to telescope into the next. This is the most feared GI complication in children, presenting with severe colicky pain and sometimes a palpable mass, and it requires urgent imaging and reduction, occasionally surgery.
• Gastrointestinal hemorrhage. Vasculitis of the gut vessels can cause bleeding, ranging from occult blood in the stool to frank GI hemorrhage that needs medical attention.
• Other GI features. Crampy abdominal pain, nausea, vomiting, and, rarely, bowel ischemia or perforation.

Recurrence Risk and Triggers

IgA vasculitis recurs in a notable minority of patients, often within the first several months after the initial episode, and recurrences are usually milder. Recognizing the triggers helps patients and families stay alert:

• Infections. Upper respiratory infections, especially streptococcal, are the classic precipitant and a common trigger for recurrence, fitting the mucosal-IgA model of the disease.
• Foods. While diet is not a proven cause, some patients and clinicians observe flares in relation to certain foods; this is individual and not well established, and any dietary change should be discussed with the care team rather than self-imposed restrictively, especially in a growing child.
• Medications. Certain drugs have been associated with triggering IgA vasculitis in some cases; any new medication coinciding with a flare is worth mentioning to the physician.

Adult vs Pediatric IgA Vasculitis at a Glance

Feature	Pediatric (children)	Adult
Frequency	Most common form; ~90% of all cases, peak ages 3-10	Less common; tends to present and behave differently
Typical trigger	Often a preceding upper respiratory or strep infection	Trigger less often identified; drug or malignancy associations more considered
Severity	Usually milder and self-limited	More severe and more often persistent
Renal involvement	Common but usually mild and transient; CKD uncommon	More frequent and more serious; 20-30% may progress to CKD
GI risk	Intussusception is a key concern	Intussusception rare; GI bleeding still possible
Treatment intensity	Often supportive care alone	More likely to need corticosteroids and immunosuppression
Supervision note	Physician supervision mandatory; never supplement without clearance	Physician supervision strongly advised, especially with kidney involvement

How Sea Moss Components Map to IgA Vasculitis Biology

Component	Relevant mechanism in IgA vasculitis	Honest limit
Fucoidan	NF-κB suppression lowering IL-6/TNF-α/IL-17; complement lectin-pathway modulation; gut mucosal barrier support; anti-neutrophil activity; possible APRIL/BAFF and mesangial effects	Almost entirely preclinical; variable, unstandardized content; not a proven disease therapy
Selenium (selenomethionine)	Cofactor for GPx1/GPx2 in renal and gut tissue; TrxR1 and selenoprotein P limit oxidative glomerular injury; supports immune balance	Narrow safe range; baseline support, not megadose or therapy
Omega-3 (EPA/DHA)	Human trial data in IgA nephropathy (Donadio, NEJM 1994/1999) slowing renal decline; resolvins/protectins; PGE2/LTB4 suppression in mesangium; proteinuria	Trial dose ~12 g/day fish oil; sea moss supplies only low-conversion ALA, so a marine omega-3 under physician care is the relevant tool
Zinc	Mucosal IgA regulation; FOXP3 Treg induction; GALT and ZIP4 gut immunity; wound/purpura healing; complement-related roles	Foundational nutrition, not an immune therapy
Iodine	Thyroid hormone production; balanced thyroid status in adults	Variable, high content; children especially sensitive to iodine excess; least directly relevant

Using Sea Moss Thoughtfully With IgA Vasculitis

If, and only if, the treating physician agrees it is appropriate, these principles keep it sensible, and they matter doubly when a child is involved.

Frequently Asked Questions

Related Guides

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. IgA vasculitis (Henoch-Schönlein purpura) is an immune-mediated small-vessel vasculitis that requires management by a qualified physician, including monitoring of the kidneys and, in children, vigilance for gastrointestinal complications. It is predominantly a pediatric condition, and any decision involving a child must be supervised by the treating pediatrician or specialist. Sea moss is a whole food and nutritional supplement only and may support general nutritional status; it is not a treatment or cure. The omega-3 trial evidence referenced here was conducted in IgA nephropathy at pharmaceutical-scale doses and does not establish that sea moss alters the course of IgA vasculitis. Consult your qualified healthcare provider before making any changes to your or your child's routine.